Treatment of mild to moderate community-acquired pneumonia in previously healthy children: an Italian intersociety consensus (SIPPS-SIP-SITIP-FIMP-SIAIP-SIMRI-FIMMG-SIMG).
Antibiotic therapy
Community-acquired pneumonia
Pediatric infectious diseases
Primary care
Respiratory infections
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
19 Oct 2024
19 Oct 2024
Historique:
received:
02
08
2024
accepted:
08
10
2024
medline:
20
10
2024
pubmed:
20
10
2024
entrez:
19
10
2024
Statut:
epublish
Résumé
Community-acquired pneumonia (CAP) is an acute infection of the lung parenchyma acquired outside the hospital or other healthcare settings, typically affecting previously healthy individuals. This intersociety consensus aims to provide evidence-based recommendations for the antibiotic treatment of mild to moderate CAP in previously healthy children in Italy.A systematic review was conducted to identify the most recent and relevant evidence. Embase, Scopus, PubMed, and Cochrane databases were systematically screened, with a date restriction from 2012 to April 2024, but without language limitations. The review included studies conducted in high-income countries on antibiotic therapy in children over 3 months of age diagnosed with mild-moderate CAP. The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methods. The final recommendations were obtained through a Delphi consensus of an expert panel.Amoxicillin is the first-line treatment if the child is at least immunized against Haemophilus influenzae type b (low/very low quality of evidence, strong recommendations), while amoxicillin-clavulanate or second- or third-generation cephalosporins should be prescribed for those unimmunized or with incomplete immunization coverage for both H. influenzae type b and Streptococcus pneumoniae (low/very low quality of evidence, strong recommendations). Macrolides should be considered in addition to amoxicillin in children over 5 years old, if symptoms persist and the clinical condition remains good after 48 h of therapy (low/very low quality of evidence, strong recommendations). The dosage of amoxicillin is 90 mg/kg/day divided in three doses, although two doses could be considered to improve compliance (moderate quality of evidence, weak recommendations). A five-day duration of therapy is recommended, with clinical monitoring and re-assessment approximately 72 h after the start of antibiotic treatment to evaluate symptom resolution (moderate quality of evidence, strong recommendations).To improve the management of CAP in pediatric patients, we have developed this consensus based on a thorough review of the best available evidence and extensive discussions with an expert panel. However, further efforts are needed. Future research should focus on enhancing diagnostic accuracy, optimizing antibiotic utilization, comparing the efficacy of different antibiotic regimens, and determining the optimal dosage and duration of treatment in different setting.
Identifiants
pubmed: 39427174
doi: 10.1186/s13052-024-01786-8
pii: 10.1186/s13052-024-01786-8
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Systematic Review
Practice Guideline
Consensus Development Conference
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
217Informations de copyright
© 2024. The Author(s).
Références
Bianchini S, Argentiero A, Camilloni B, Silvestri E, Alunno A, Esposito S. Vaccination against paediatric respiratory pathogens. Vaccines (Basel). 2019;7(168).
Liu L, Johnson H, Cousens S, Perin J, Scott S, Lawn J, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;9832:2151–61.
doi: 10.1016/S0140-6736(12)60560-1
Walker C, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta Z, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405–16.
pubmed: 23582727
pmcid: 7159282
doi: 10.1016/S0140-6736(13)60222-6
Zar H, Ferkol T. The global burden of respiratory disease-impact on child health. Pediatr Pulmonol. 2014;49(5):430–4.
pubmed: 24610581
doi: 10.1002/ppul.23030
WHO. World Health Statistics. World Health Organization. 2015. https://www.who.int/docs/default-source/gho-documents/world-health-statistic-reports/world-health-statistics-2015.pdf . 2015;available.
McIntosh K. Community-acquired pneumonia in children. N Engl J Med. 2002;346(6):429–37.
pubmed: 11832532
doi: 10.1056/NEJMra011994
Cardinale F, Cappiello AR, Mastrototaro MF, Pignatelli M, Esposito S. Community-acquired pneumonia in children. Early Hum Dev. 2013;89(SUPPL3).
Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. Clin Infect Dis. 2011;53(7):25–76.
doi: 10.1093/cid/cir531
Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66(Suppl 2):ii1–23. http://thorax.bmj.com/cgi/doi/ https://doi.org/10.1136/thoraxjnl-2011-200598
Esposito S, Cohen R, Domingo JD, Pecurariu OF, Greenberg D, Heininger U et al. Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? 31, Pediatr Infect Disease J. 2012.
Michelow I, Olsen K, Lozano J, Rollins N, Duffy L, Ziegler T, et al. Epidemiology and clinical characteristics of Community-Acquired Pneumonia in Hospitalized Children. Pediatrics. 2004;113(4):701–7.
pubmed: 15060215
doi: 10.1542/peds.113.4.701
Esposito S, Daleno C, Prunotto G, et al. Impact of viral infections in children with community-acquired pneumonia: results of a study of 17 respiratory viruses. Influenza Other Respir Viruses. 2013;7:18–26.
pubmed: 22329841
doi: 10.1111/j.1750-2659.2012.00340.x
Falade A, Ayede A. Epidemiology, aetiology and management of childhood acute community-acquired pneumonia in developing countries–a review. Afr J Med Med Sci. 2011;40(4):293–308.
pubmed: 22783679
Esposito S, Bosis S, Cavagna R, Faelli N, Begliatti E, Marchisio P et al. Characteristics of Streptococcus pneumoniae and Atypical Bacterial Infections in Children 2–5 Years of Age with Community-Acquired Pneumonia. Community-Acquired Pneumonia in Children • CID. 2002. https://academic.oup.com/cid/article/35/11/1345/428092
Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C, Consolo S, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med. 2011;105(12):1939–45.
pubmed: 21959024
doi: 10.1016/j.rmed.2011.09.003
Principi N, Esposito S. Biomarkers in pediatric community-acquired pneumonia. International Journal of Molecular Sciences. Volume 18. MDPI AG; 2017.
Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7).
Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children < 5 years: An active prospective nationwide surveillance. Vaccine. 2014;32(27):3452–9. https://doi.org/10.1016/j.vaccine.2014.03.065
Bamberger EE, Ben-Shimol S, Abu Raya B, Katz A, Givon-Lavi N, Dagan R, et al. Pediatric invasive haemophilus influenzae infections in Israel in the era of haemophilus influenzae type b vaccine: a nationwide prospective study. Pediatr Infect Disease J. 2014;33(5):477–81.
doi: 10.1097/INF.0000000000000193
Istituto Superiore di Sanità. Dati e evidenze disponibili per l’utilizzo dei vaccini anti-pneumococcici nei soggetti a rischio di qualsiasi età e per l’eventuale ampliamento dell’offerta ai soggetti anziani. 2013;66.
Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination Coverage among children aged 19–35 months — United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67(40):1123–8.
pubmed: 30307907
pmcid: 6181261
doi: 10.15585/mmwr.mm6740a4
Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kolasa M. National, State, and selected local Area Vaccination Coverage among children aged 19–35 months — United States, 2014 Holly. MMWR Morb Mortal Wkly Rep. 2015;64(33):890.
doi: 10.15585/mmwr.mm6433a1
Black CL, Yankey D, Kolasa M, Immunization Services Div, National Center for Immunization and Respiratory Diseases CDC, National. State, and local Area Vaccination Coverage among children aged 19–35 months — United States, 2012. Pediatr Infect Disease J. 2013;62(36):733–40.
Wooten KG, Kolasa M, Singleton J, Shefer A, mmunization Svcs Div, National Center For Immunization and Respiratory Diseases C, National. State, and local Area Vaccination Coverage among children aged 19–35 months — United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(36):1171–7.
Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kolasa M. National, State, and local Area Vaccination Coverage among children aged 19–35 months --- United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(33):921–6.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Online). 2017;358.
Wells G, Shea B, D O’Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
The GRADE Working Group, Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. Updated November 2021.
Biondi E, McCulloh R, Alverson B, Klein A, Dixon A, Ralston S. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 2014;133(6):1081–90.
pubmed: 24864174
doi: 10.1542/peds.2013-3729
Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Reviews. 2015;2015(1).
Lodha R, Kabra SK, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Reviews. 2013;2013:6.
Kuitunen I, Jääskeläinen J, Korppi M, Renko M. Antibiotic treatment duration for community acquired pneumonia in outpatient children in high-income countries – a systematic review and meta-analysis. Clin Infect Dis. 2022;1–6.
Li Q, Zhou Q, Florez ID, Mathew JL, Shang L, Zhang G, et al. Short-course vs Long-Course Antibiotic Therapy for Children with Nonsevere Community-Acquired Pneumonia: a systematic review and Meta-analysis. JAMA Pediatrics. Volume 176. American Medical Association; 2022. pp. 1199–207.
Gao Y, Liu M, Yang K, Zhao Y, Tian J, Pernica JM et al. Shorter Versus Longer-term Antibiotic Treatments for Community-Acquired Pneumonia in Children: A Meta-analysis. 2023;151.
Marques IR, Calvi IP, Cruz SA, Sanchez LMF, Baroni IF, Oommen C, et al. Shorter versus longer duration of Amoxicillin-based treatment for pediatric patients with community-acquired pneumonia: a systematic review and meta-analysis. Eur J Pediatr. 2022;181(11):3795–804.
doi: 10.1007/s00431-022-04603-8
Al Saeedy D, Gulam SM, Gillani SW, Al-Salloum J, Moosvi A, Eissa M. Comparative efficacy of Beta-lactams and macrolides in the treatment of Pediatric Pneumonia: a systematic review. Curr Pediatr Rev. 2020;16(4):307–13.
pubmed: 32895041
doi: 10.2174/1573396316666200907115800
Ashy N, Alharbi L, Alkhamisi R, Alradadi R, Eljaaly K. Efficacy of erythromycin compared to clarithromycin and azithromycin in adults or adolescents with community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. J Infect Chemother. 2022;28(8):1148–52.
pubmed: 35523718
doi: 10.1016/j.jiac.2022.04.020
Bielicki JA, Stöhr W, Barratt S, Dunn D, Naufal N, Roland D, et al. Effect of Amoxicillin Dose and Treatment Duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: the CAP-IT Randomized Clinical Trial. JAMA - J Am Med Association. 2021;326(17):1713–24.
doi: 10.1001/jama.2021.17843
Pernica JM, Harman S, Kam AJ, Carciumaru R, Vanniyasingam T, Crawford T, et al. Short-course antimicrobial therapy for Pediatric Community-Acquired Pneumonia: the SAFER randomized clinical trial. JAMA Pediatr. 2021;175(5):475–82.
pubmed: 33683325
doi: 10.1001/jamapediatrics.2020.6735
Williams DJ, Creech CB, Walter EB, Martin JM, Gerber JS, Newland JG, et al. Short-vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: the SCOUT-CAP randomized clinical trial. JAMA Pediatr. 2022;176(3):253–61.
pubmed: 35040920
doi: 10.1001/jamapediatrics.2021.5547
Greenberg D, Givon-Lavi N, Sadaka Y, Ben-Shimol S, Bar-Ziv J, Dagan R. Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial. Pediatr Infect Disease J. 2014;33(2):136–42.
doi: 10.1097/INF.0000000000000023
Ambroggio L, Test M, Metlay JP, Graf TR, Blosky MA, Macaluso M, et al. Comparative effectiveness of Beta-lactam vs. macrolide monotherapy in children with Pneumonia diagnosed in the outpatient setting. Pediatr Infect Dis J 2015. 2015;34(8):839–42.
doi: 10.1097/INF.0000000000000740
Ambroggio L, Taylor JA, Tabb LP, Newschaffer CJ, Evans AA, Shah SS. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia. Journal of Pediatrics. 2012;161(6):1097–1103.e1. https://doi.org/10.1016/j.jpeds.2012.06.067
Ambroggio L, Test M, Metlay JP, Graf TR, Blosky MA, Macaluso M, et al. Beta-Lactam Versus Beta-Lactam/Macrolide Therapy in Pediatric Outpatient Pneumonia. Pediatr Pulmonol. 2016;51(5):541–548148.
pubmed: 26367389
doi: 10.1002/ppul.23312
Donà D, Zingarella S, Gastaldi A, Lundin R, Perilongo G, Frigo AC, et al. Effects of clinical pathway implementation on antibiotic prescriptions for pediatric community-acquired pneumonia. PLoS ONE. 2018;13(2):1–15.
doi: 10.1371/journal.pone.0193581
Lipsett SC, Hall M, Ambroggio L, Hersh AL, Shah SS, Brogan TV et al. Antibiotic Choice and Clinical Outcomes in Ambulatory Children with Community-Acquired Pneumonia. Journal of Pediatrics. 2021;229:207–215.e1. https://doi.org/10.1016/j.jpeds.2020.10.005
Shapiro DJ, Hall M, Lipsett SC, Hersh AL, Ambroggio L, Shah SS et al. Short- Versus Prolonged-Duration Antibiotics for Outpatient Pneumonia in Children. Journal of Pediatrics. 2021;234:205–211.e1. https://doi.org/10.1016/j.jpeds.2021.03.017
Ambroggio L, Cotter J, Hall M, Shapiro DJ, Lipsett SC, Hersh AL, et al. Management of Pediatric Pneumonia: a Decade after the Pediatric Infectious Diseases Society and Infectious Diseases Society of America Guideline. Clin Infect Dis. 2023;77(11):1604–11.
pubmed: 37352841
pmcid: 11487097
doi: 10.1093/cid/ciad385
Queen MA, Myers AL, Hall M, Shah SS, Williams DJ, Auger KA et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia. Pediatrics. 2014;133(1).
Newman RE, Hedican EB, Herigon JC, Williams DD, Williams AR, Newland JG. Impact of a guideline on management of children hospitalized with community-acquired pneumonia. Pediatrics. 2012;129(3).
Williams DJ, Hall M, Shah SS, Parikh K, Tyler A, Neuman MI et al. Narrow vs broad-spectrum antimicrobial therapy for children hospitalized with pneumonia. Pediatrics. 2013;132(5).
Williams DJ, Edwards KM, Self WH, Zhu Y, Arnold SR, McCullers JA, et al. Effectiveness of ß-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia. JAMA Pediatr. 2017;171(12):1184–91.
pubmed: 29084336
pmcid: 6583650
doi: 10.1001/jamapediatrics.2017.3225
Puzz L, Plauche EA, Cretella DA, Harrison VA, Wingler MJB. Evaluation of a Pediatric Community-Acquired Pneumonia Antimicrobial stewardship intervention at an Academic Medical Center. Antibiotics. 2023;12(4).
Dinur-Schejter Y, Cohen-Cymberknoh M, Tenenbaum A, Brooks R, Averbuch D, Kharasch S, et al. Antibiotic treatment of children with community-acquired pneumonia: comparison of penicillin or ampicillin versus cefuroxime. Pediatr Pulmonol. 2013;48(1):52–8.
pubmed: 22431471
doi: 10.1002/ppul.22534
Breuer O, Blich O, Cohen-Cymberknoh M, Averbuch D, Kharasch S, Shoseyov D, et al. Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy. Pediatr Pulmonol. 2015;50(5):495–502.
pubmed: 25652187
doi: 10.1002/ppul.23159
Hazir T, Qazi SA, Nisar Y, Bin, Maqbool S, Asghar R, Iqbal I, et al. Comparison of standard versus double dose of Amoxicillin in the treatment of non-severe pneumonia in children aged 2–59 months: a multi-centre, double blind, randomised controlled trial in Pakistan. Arch Dis Child. 2007;92(4):291–7.
pubmed: 16547082
doi: 10.1136/adc.2005.092494
Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J 29(11):1043–6.
Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the Pneumococcal Conjugate Vaccine on Drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;355:11–20.
Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother. 2009;63(3):511–9.
pubmed: 19174454
doi: 10.1093/jac/dkn538
Rasch JR, Mogabgab WJ. Therapeutic effect of erythromycin on Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother (Bethesda). 1965;5.
Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Disease J. 2007;26(10):868–78.
doi: 10.1097/INF.0b013e3180cbd2c7
Plouffe JF. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis. 2000;31(SUPPL 2):35–9.
doi: 10.1086/314058
Atkinson M, Lakhanpaul M, Smyth A, Vyas H, Weston V, Sithole J, et al. Comparison of oral Amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. Thorax. 2007;62(12):1102–6.
pubmed: 17567657
pmcid: 2094276
doi: 10.1136/thx.2006.074906
Roord JJ, Wolf BHM, Goossens MMHT, Kimpen JLL. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob Agents Chemother. 1996;40(12):2765–8.
pubmed: 9124837
pmcid: 163618
doi: 10.1128/AAC.40.12.2765
Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft C. Mycoplasma pneumoanie and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarothromycin vs. erythromycin ethylsuccinate. Pediatr. 1995;14(6):471–7.
Lynch IIIJP, Martinez FJ. Clinical Relevance of Macrolide-Resistant Streptococcus pneumoniae for Community-Acquired Pneumonia. Clinical Infectious Diseases. 2002;(34(Suppl 1)):S27–46. https://academic.oup.com/cid/article/34/Supplement_1/S27/510320
Riedel S, Beekmann SE, Heilmann KP, Richter SS, Garcia-De-Lomas J, Ferech M, et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis. 2007;26(7):485–90.
pubmed: 17551759
doi: 10.1007/s10096-007-0321-5
Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clinical Microbiology Reviews. Volume 29. American Society for Microbiology; 2016. pp. 525–52.
Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev. 2007;20:368–89.
pubmed: 17428889
pmcid: 1865592
doi: 10.1128/CMR.00040-06
Broyles AD, Banerji A, Barmettler S, Biggs CM, Blumenthal K, Brennan PJ et al. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. Journal of Allergy and Clinical Immunology: In Practice. American Academy of Allergy, Asthma and Immunology; 2020;8:S16–116.
Gomes ER, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N et al. Drug hypersensitivity in children: Report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy: European Journal of Allergy and Clinical Immunology. Blackwell Publishing Ltd; 2016;71:149–61.
Romano A, Atanaskovic-Markovic M, Barbaud A, Bircher AJ, Brockow K, Caubet JC, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams — an EAACI position paper. Allergy: Eur J Allergy Clin Immunol. 2020;75(6):1300–15.
doi: 10.1111/all.14122
Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International Consensus on drug allergy. Allergy: Eur J Allergy Clin Immunol. 2014;69(4):420–37.
doi: 10.1111/all.12350
Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg. 2007;136:340–7.
Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics. 2005;115:1048–57.
Pichichero ME. Use of selected cephalosporins in penicillin-allergic patients: a paradigm shift [Diagnostic Microbiology and Infectious Disease 57, S13-S18, 2007] ( https://doi.org/10.1016/j.diagmicrobio.2006.12.004 ). Diagn Microbiol Infect Dis. 2008;57:S13–8.
doi: 10.1016/j.diagmicrobio.2006.12.004
Costenaro P, Cantarutti A, Barbieri E, Scamarcia A, Oletto A, Sacerdoti P, et al. Antibiotic prescriptions for children with community-acquired Pneumonia: findings from Italy. Pediatr Infect Disease J. 2021;40(2):130–6.
doi: 10.1097/INF.0000000000002934